Investors
Mauna Kea Technologies
Stock Information
Mauna Kea Technologies
Stock Information
Stay up to date on all our investor news
0,3520€
Last updated
15/09/2024 - 12:14
-1,68%
€10.5M
Sales in 2023
+42%
Sales growth in 2023
excluding exchange rates
+52%
PPU growth in 2023
excluding exchange rates
Events and Presentations
Financial Results
GovernanceÂ
Voting Rights Information – July 2024
Mauna Kea Technologies Announces its Sales and Achievements For the Second Quarter 2024
Half-Year Liquidity Contract Statement for H1 2024 with the Brokerage Firm Gilbert Dupont
Voting Rights Information – June 2024
Mauna Kea Technologies announces results of its Combined General Meeting of June 6, 2024
News
Mauna Kea Technologies Announces Endorsement from The American Foregut Society for Payor Policy Coverage of Cellvizio®Â
Mauna Kea Technologies Announces its Sales and Achievements For the Second Quarter 2024
Mauna Kea Technologies Unveils CellTolerance, a Subsidiary Dedicated to its Unique Program for the Detection and Treatment of Food Intolerances
Shareholding Structure
A long term vision shared by major strategic shareholders: Johnson & Johnson (NYSE: JNJ) and Telix Pharmaceuticals (ASX : TLX)
Stock Information
STOCK MARKET DATA
Listed on Euronext Growth Paris
Initial listing : July 6, 2011
The number of outstanding shares is : 64,702,127
Industry : healthcare (4000)
Sector : Medical equipment and healthcare services (4530)
IDENTIFICATION CODES
ISINÂ : FR0010609263
Ticker : ALMKT
ANALYST COVERAGE
Guillaume Cuvillier
Raphaël Génin
STATUTORY AUDITORS
• EY and Others, represented by Mr Franck SEBAG, 1-2 place des Saisons, 92400 Courbevoie- Paris La Défense, France
• Exco Socodec, represented by Monsieur Olivier Gallezot, 51, Avenue Françoise Giroud, Parc Valmy, 21066 Dijon
LIQUIDITY CONTRACT
Gilbert Dupont